McKesson nets 44 deals for molecular, genetic tests

Forty-four managed care organizations have licensed McKesson's molecular and genetic diagnostic management technologies, including recent new health plan customers Molina Healthcare, Paramount Healthcare and Providence Health Plans, part of the five-state Providence Health & Services.

San Francisco-based McKesson said its molecular and genetic testing management offerings include InterQual Molecular Diagnostic Criteria, Clear Coverage, Clear Orders and analytics services. This combination provides evidence-based clinical decision support for more than 500 molecular and genetic tests.

The Clear Coverage and Clear Orders tools automate notifications and authorizations while giving providers access to medical, network and benefit policies, as well as validating coverage prior to testing and forward orders to appropriate labs. InterQual Criteria clinical decision support content is included in Clear Coverage to provide medical necessity guidelines based on evidence-based medicine.

 

 

 

 

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?